NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $337 | -61.0% | 20,838 | 0.0% | 0.01% | -64.7% |
| Q2 2023 | $865 | -31.0% | 20,838 | 0.0% | 0.02% | -37.0% |
| Q1 2023 | $1,253 | -18.0% | 20,838 | 0.0% | 0.03% | -20.6% |
| Q4 2022 | $1,528 | -99.9% | 20,838 | 0.0% | 0.03% | -12.8% |
| Q3 2022 | $1,583,000 | +9.3% | 20,838 | 0.0% | 0.04% | +14.7% |
| Q2 2022 | $1,448,000 | +39.9% | 20,838 | +66.9% | 0.03% | +9.7% |
| Q1 2022 | $1,035,000 | +10.3% | 12,487 | 0.0% | 0.03% | +19.2% |
| Q4 2021 | $938,000 | -18.3% | 12,487 | +26.3% | 0.03% | -38.1% |
| Q3 2021 | $1,148,000 | -47.7% | 9,886 | 0.0% | 0.04% | -52.8% |
| Q2 2021 | $2,193,000 | +36.6% | 9,886 | -18.6% | 0.09% | +27.1% |
| Q1 2021 | $1,605,000 | -23.6% | 12,144 | 0.0% | 0.07% | -28.6% |
| Q4 2020 | $2,101,000 | +192.6% | 12,144 | +88.4% | 0.10% | +3.2% |
| Q3 2020 | $718,000 | – | 6,447 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |